Post stroke dementia and Post stroke depression by ZLATKO TRKANJEC
Post stroke dementia and Post stroke depression
Abstract
Stroke is the rapid loss of brain function due to disturbance in the blood
supply to the brain causing predominantly motor and sensory symptoms.
However, stroke can cause some other symptoms. Post stroke dementia and
depression are probably the most important non-motor consequences of
stroke. Post stroke dementia and depression are important and often over-
looked symptoms following stroke. Treatment options for Post stroke de-
mentia and depression are still limited, therefore diagnosis of Post stroke
dementia and depression is very important because it could lead to preven-
tion of dementia and depression by appropriate control of vascular risk
factors. Primary prevention depend on early identification and appropriate
control of vascular risk factors, while secondary prevention must include
energetic therapy to prevent stroke recurrence.
POST STROKE DEMENTIA
Introduction
Dementia is defined as a neurological syndrome consisting of im-paired cognition that is severe enough to interfere with eveyday
activities of daily living (1). Post stroke dementia represents part of
vascular dementia (VaD) which is the most common form of dementia
in the elderly after Alzheimer’s dementia (AD) (2). The term vascular
dementia identifies patients with severe cognitive loss from cerebrovas-
cular disease, either after large ischemic or hemorrhagic strokes, lacu-
nar infarcts, microscopic cortical infarcts that do not cause clinical
symptoms (silent strokes), or from cardiac and circulatory disorders
causing incomplete white matter infarction (3). Recently a concept of
vascular cognitive impairment (VCI) was introduces (4, 5, 6). The
concept of VCI includes patients with classic vascular risk factors and
some degree of cognitive loss, but not dementia. The term vascular
cognitive impairment (VCI) has been used to refer to all forms of mild
to severe cognitive impairment that are associated with a vascular
insult, whether they meet criteria for vascular dementia or not (7-11).
This form of impairment includes those who have cognitive dysfunc-
tion associated with stroke, multiple cortical infarcts, multiple sub-
cortical infarcts, silent infarcts, strategic infarcts, multiple small vessel
disease with white matter lesions, and lacunar infarcts. There is believe
that appropriate prevention measures and treatment of the vascular risk
factors could prevent the progression of VCI to vascular dementia
(10-11), because it was recently demonstrated in the Canadian Study
on Health and Aging (12) that some patients with VCI improved
spontaneously after a 5-year follow-up, indicating that VCI does not
always have to progres to vascular dementia.
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Overview
In an attempt to approach the heterogeneity of the
pathophysiology associated with VaD, a number of re-
searchers have subclassified vascular dementia according
to the pathophysiology of the lesion that causes the cog-
nitive deficit. One simplified subclassification includes
Post stroke dementia, subcortical VaD, and AD plus VaD
(mixed dementia) (10). Post stroke dementia is defined
as a cognitive impairment resulting from a thrombo-
embolic or hemorrhagic event causing cognitive symp-
toms severe enough to impair everyday social and oc-
cupational functioning. Subcortical VaD is caused by
lacunar infarcts and white matter lesions.
Epidemiology and Risk Factors
Population-based epidemiological studies and neuro-
pathology data have confirmed that vascular dementia is
responsible for about 20% of cases of dementia and that
vascular lesions are commonly found in patients with
AD. The role of vascular risk factors and strokes in AD is
an area of intensive research (13-17), and decreased inci-
dence of AD and vascular dementia was observed with
control of hypertension (18), and with the use of statins
(19).
Age is the most significant risk factor for any demen-
tia; however, other factors associated with health status
earlier in life may predispose older adults to developing
VaD. Atherosclerotic risk factors such as smoking, hyper-
tension, myocardial infarctions, hyperlipidemia, and dia-
betes mellitus predispose older adults to cerebrovascular
disease causing VaD (20). Additionally, the presence of
stroke-related factors as a consequence of hemorrhagic,
ischemic, or embolic events in the brain may also cause
VaD (21). The location and size of the stroke can also
cause significant cerebral tissue loss and white matter
disease, leading to VaD (20).
Based on projected figures for the growing proportion
of elderly persons and increased incidence of ischemic
heart disease and stroke, it has been postulated that vas-
cular dementia may become the most common cause of
dementia in the near future because it affects 30% of
ischemic strokes and 26% of patients with congestive
heart failure due to hypoperfusion (4, 22). On the other
hand, Post stroke dementia (multi-infarct dementia) often
remains underecognized (23), and it is rare to diagnose
vascular dementia after congestive heart failure, after
major surgery in the elderly, or after coronary artery
bypass graft.
Subcortical ischemic vascular dementia results from
small-vessel disease, and produces lacunar strokes and
incomplete white matter infarction (24) having relatively
poor prognosis of lacunes in terms of cognitive outcome
(25). Furthermore, silent lacunar strokes appear to double
the risk of dementia (26). It has been postulated that
chronic brain edema from damage of the blood-brain
barrier could explain their poor outcome (27). Lacunes are
markers of small-vessel disease and should prompt a
search for diagnosis and treatment of relevant risk factors.
Pathophysiology
Vascular dementia results from brain injury caused by
stroke and cerebral ischemia or haemorrhage. Single ische-
mic or thromboembolic infarcts occurring in strategic
areas of the dominant hemisphere (eg, angular gyri, me-
diodorsal thalamus, anterior thalamus) may cause a de-
mentia-like syndrome without the involvement of large
volumes of cerebral matter. In general, volume of tissue
loss is a poor predictor of the severity of the cognitive
impairment. More commonly, progressive cognitive de-
ficits and dementia can result from multiple temporally
placed small cerebral infarcts. Frontal subcortical regions
supplied by small penetrating arterioles may be especial-
ly prone to degenerative changes in patients with poorly
controlled hypertension, diabetes mellitus, or both. A less
common cause of vascular dementia is global hypoxic-
-ischemic injury (eg, following cardiac arrest). Irrever-
sible cognitive impairment is frequently observed fol-
lowing coronary bypass surgery (28).
Less understood form of vascular dementia is Bins-
wanger encephalopathy, causing mostly subcortical de-
mentia features. Postmortem, myelin loss is observed
and is most prominent in the hemispheric deep white
matter. Axonal drop out is also observed with little or no
signs of inflammation. Neuroimaging shows decreased
white matter density on computer tomography (CT)
scanning and decreased white matter intensity on mag-
netic resonance imaging (MRI). However, frequently on
these neuroimaging scans lacunar strokes are observed.
Dementia associated with cerebrovascular disease is
also observed in a rare genetic condition, ie, cerebral
autosomal dominant arteriopathy with subcortical in-
farcts and leukoencephalopathy – CADASIL (29). Af-
fected patients often present with migraines with aura.
Recurrent strokes start when the patients are aged 30-50
years. Multiple lacunar infarcts, mainly in the frontal
white matter and basal ganglia, lead to progressive cog-
nitive decline and finally dementia. However, cognitive
decline is thought to begin even before strokes occur,
suggesting that chronic cerebral hypoperfusion in the
absence of overt stroke might be sufficient to cause sig-
nificant neuronal circuit disruption.
Diagnosis
A diagnosis of VaD would be appropriate for an indi-
vidual who presents with an acute onset and stepwise
progression of cognitive impairment (30). Three specific
elements are required for a clinician to diagnose an indi-
vidual with VaD: the first is demonstration of cognitive
impairment, the second is existence of cerebrovascular
disease, and the third is the relationship between two
disorders (30, 31, 32). Many individuals with VaD have a
generalized cognitive deficit with less striking memory
loss (6, 9). In fact, a more common form of cognitive
impairment associated with VaD is compromised execu-
tive functioning, which involves goal-directed behaviour,
initiation of sequences, and problem-solving abilities (6,
33). Cerebrovascular subcortical lesions in the prefrontal
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cortex resulting in subcortical VaD can often cause cogni-
tive impairments associated with executive functioning.
To determine if executive impairments exist in individuals
with VaD, specific neuropsychological tests of executive
functioning such as the Trail-Making Test, the Executive
Interview, and the Clock Drawing Test may be used (6).
There are several nonspecific clinical symptoms associated
with vascular dementia. Individuals with typical subcorti-
cal lesions may display extrapyramidal symptoms and insta-
bility leading to falls. Urinary frequency and inconti-
nence, as well as dysarthria and dysphagia, are common
symptoms (10). The Hachinski Ischemic Scale accounts
for factors associated with vascular development of de-
mentia such as the onset of the cognitive impairment, the
risk factors related to stroke, behavioural abnormalities
such as depression and emotional incontinence, and focal
neurological symptoms (21). A score lower than 4 renders
a diagnosis of AD, whereas a score of greater than 7 is
classified as multi-infarct dementia (9, 34), while score of
five to six may suggest the so called mixed dementia –
Alzheimer’s dementia and vascular dementia. The patient
must demonstrate some form of cerebrovascular patho-
logy as displayed by brain imaging studies (CT or MRI).
Neuroimaging studies demonstrate vascular lesions that
may differ in size depending on the degree of vascular
pathology. These lesions range from a single lacunar stroke
to multiple cortico-subcortical strokes and periventricular
white matter ischemia (6, 9). A final factor required for the
diagnosis of VaD is the fact that cognitive impairment
occurred some time after the cerebrovascular event, usu-
ally within three months, but this three months criterion is
being disputed in some discussions (6, 8).
The National Institute for Neurological Disorders
and Stroke-Association Internationale pour la Recherche
et l’Enseignement en Neurosciences (NINDS-AIREN)
defined criteria for VaD (31). However, these criteria,
published in 1993, i.e. almost 20 years ago, are considered
outdated. Therefore recently the American Heart As-
sociation and the American Stroke Association support-
ed by the American Academy of Neurology and the
Alzheimer’s Association published criteria for vascular
cognitive impairment and they introduced the term: vas-
cular mild cognitive impairment (VaMCI) similar to mild
cognitive impairment and present diagnostic criteria for
it (36). These criteria define VaD as probable VaD and
possible VaD, and VaMCI as probable, possible and un-
stable VaMCI (Table 1).
TABLE 1.
Vascular Cognitive Impairment
1. The term VCI characterizes all forms of cognitive
deficits from VaD to MCI of vascular origin.
2. These criteria cannot be used for subjects who have an
active diagnosis of drug or alcohol abuse/dependence.
Subjects must be free of any type of substance for at
least 3 months.
3. These criteria cannot be used for subjects with de-
lirium.
Dementia
1. The diagnosis of dementia should be based on a de-
cline in cognitive function from a prior baseline and a
deficit in performance in ³ 2 cognitive domains that
are of sufficient severity to affect the subject’s activities
of daily living.
2. The diagnosis of dementia must be based on cognitive
testing, and a minimum of 4 cognitive domains should
be assessed: executive/attention, memory, language,
and visuospatial functions.
3. The deficits in activities of daily living are independent
of the motor/sensory sequelae of the vascular event.
Probable VaD
1. There is cognitive impairment and imaging evidence
of cerebrovascular disease and:
a. There is a clear temporal relationship between a
vascular event (eg, clinical stroke)and onset of
cognitive deficits, or
b. There is a clear relationship in the severity and
pattern of cognitive impairment andthe presen-
ce of diffuse, subcortical cerebrovascular disease
pathology(eg, as inCADASIL).
2. There is no history of gradually progressive cognitive
deficits before or after the stroke that suggests the pre-
sence of a nonvascular neurodegenerative disorder.
PossibleVaD
There is cognitive impairment and imaging evidence
of cerebrovascular disease but
1. There is no clear relationship (temporal, severity, or
cognitive pattern) between the vascular disease (eg,
silent infarcts, subcortical small-vessel disease) and
the cognitive impairment.
2. There is insufficient information for the diagnosis of
VaD (eg, clinical symptoms suggest the presence of
vascular disease, but no CT/MRI studies are available).
3. Severity of aphasia precludes proper cognitive assess-
ment. However, patients with documented evidence
of normal cognitive function (eg, annual cognitive
evaluations) before the clinical event that caused
aphasia could be classified as having probable VaD.
4. There is evidence of other neurodegenerative diseases
or conditions in addition to cerebrovascular diseaset
hat may affect cognition, such as:
a. A history of other neurodegenerative disorders
(eg, Parkinson disease, progressivesupranuclear
palsy, dementia with Lewy bodies);
b. The presence of Alzheimer disease biology is
confirmed by biomarkers (eg, PET,CSF, amyloid
ligands) or genetic studies (eg, PS1 mutation);or
c. A history of active cancer or psychiatric or meta-
bolic disorders that may affectcognitive function.
VaMCI
1. VaMCI includes the 4 subtypes proposed for the classi-
fication of MCI: amnestic, amnestic plus other domains,
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nonamnestic single domain, and nonamnestic multi-
ple domain.
2. The classification of VaMCI must be based on cog-
nitive testing, and a minimum of 4 cognitive domains
should be assessed: executive/attention, memory, langu-
age, and visuospatial functions. The classification should
be based on an assumption of decline in cognitive
function from a prior baseline and impairment in at
least 1 cognitive domain.
3. Instrumental activities of daily living could be normal
or mildly impaired, independent of the presence of
motor/sensory symptoms.
Probable VaMCI
1. There is cognitive impairment and imaging evidence
of cerebrovascular disease and:
a. There is a clear temporal relationship between a
vascular event (eg, clinicalstroke)and onset of
cognitive deficits, or
b. There is a clear relationship in the severity and
pattern of cognitive impairment andthe presen-
ce of diffuse, subcortical cerebrovascular disease
pathology(eg, asinCADASIL).
2. There is no history of gradually progressive cognitive
deficits before or after the stroke that suggests the pre-
sence of a nonvascular neurodegenerative disorder.
Possible VaMCI
There is cognitive impairment and imaging evidence
of cerebrovascular disease but:
1. There is no clear relationship (temporal, severity, or
cognitive pattern) between the vascular disease (eg,
silent infarcts, subcortical small-vessel disease) and
onset of cognitive deficits.
2. There is insufficient information for the diagnosis of
VaMCI (eg, clinical symptoms suggest the presence of
vascular disease, but no CT/MRI studies are available).
3. Severity of aphasia precludes proper cognitive assess-
ment. However, patients with documented evidence of
normal cognitive function (eg, annual cognitive eva-
luations) before the clinical event that caused aphasia
could be classified as having probable VaMCI.
4. There is evidence of other neurodegenerative diseases
or conditions in addition to cerebrovascular disease
that may affect cognition, such as:
a. A history of other neurodegenerative disorders
(eg, Parkinson disease, progressivesupranuclear
palsy, dementia with Lewy bodies);
b. The presence of Alzheimer disease biology is
confirmed by biomarkers (eg, PET,CSF, amyloid
ligands) or genetic studies (eg, PS1 mutation); or
c. A history of active cancer or psychiatric or meta-
bolic disorders that may affectcognitive function.
Unstable VaMCI
Subjects with the diagnosis of probable or possible
VaMCI whose symptoms revert to normal should be
classified as having „unstable VaMCI”
Clinical manifestation
Patients with VaD are cognitively impaired in execu-
tive functioning activities such as organizing, planning,
and initiating sequential events. Patients with VaD have
relatively mild memory loss but usually have early execu-
tive dysfunction, and loss of executive control function is
characterized by lack of planning, disorganized thought,
behavior, or emotion (37-40). Therefore, it is very similar
to subcortical neurogedenerative dementias, sometimes
called dysexecutive cognitive impairment. Complex acti-
vities such as cooking, dressing, and housekeeping are
predominantly affected in patients with (40, 41). How-
ever, most of the current tests for assessment of dementia
are relatively insensitive to executive function, leading to
underdiagnosis of vascular dementia. Executive dysfunc-
tion is relatively common among elderly people living in
the community, affecting one in six non-demented indi-
viduals (41 – 45). Loss of executive function is an impor-
tant cause of disability in non-demented community-
-dwelling individuals (42-45), as well as in patients with
vascular dementia (46-50), and Alzheimer’s dementia
(51). Other cognitive domains such as memory, langu-
age, visuospatial skills and motor speed, or demographic
features such as age, education and health status, have
minimal contribution to activities of daily living (ADL).
Similar conclusions were reached using two tests of exe-
cutive function, the EXIT25 and a simple clock-drawing
task (52, 53). Mini-mental state examination made no
contribution to the regression model, while depression
and physical illness contributed little additional variance
to the model.
Apathy and depression frequently occur as a con-
sequence of disruption of prefrontal circuits in patients
after stroke and these symptoms are an important com-
ponent in the development of VaD. Vascular depression
is currently recognized as an independent condition (54,
55). A study of Post stroke patients in Finland (56) con-
firmed that executive dysfunction was the main deter-
minant of abnormalities in both basic and instrumental
ADL suggesting that executive function including ins-
trumental ADL may be more sensitive for the diagnosis
of vascular dementia and could accurately measure the
effects of potential therapies. Instrumental ADL appear
to be an appropriate examination for executive function
in patients with post stroke cognitive decline (57-60),
apathy and depression, although there is no total agree-
ment with this concept (61). Other typical clinical fea-
tures of vascular dementia include cases with sudden
onset and slow or stepwise progression, often increasing
in severity with each ischemic event: fluctuations are
common and memory is only mildly affected. In VaD
gait is typically disturbed, shuffling and with short steps,
and often resembles that of patients with Parkinson’s
disease (62, 63).
Treatment
A number of medications have been used for the
symptomatic treatment of VaD, including vasodilators
such as niacin, calcium channel blockers, pentoxifylline,
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antiplatelet agents, and nootropic agents such as me-
mantine. More recently, the cholinesterase inhibitors do-
nepezil, galantamine, and rivastigmine have been stu-
died in controlled clinical trials in vascular dementia.
Cholinergic deficits in the condition may result from
ischemia of the nucleus basalis of Meynert or from inter-
ruption of cholinergic pathways by vascular lesions.
Compared with placebo, donepezil treatment groups
showed statistically significant improvement in cogni-
tion, global function, and both basic and instrumental
ADL (64, 65, 66).
Study of galantamine in vascular dementia showed a
significant improvement in the behavioral symptoms in
the treated group versus placebo (67).
The change from baseline on the neuropsychiatric
inventory score at 22 months showed that the rivastig-
mine group improved while the aspirin group deterio-
rated. Also, the rivastigmine group showed significant
improvements in executive function, behavioral symp-
toms, and caregivers’ relative stress score relative to the
aspirin group (68, 69).
Two trials of memantine in patients with mild to
moderate vascular dementia the mean ADAS-cog and
the mini-mental state examination scores improved sig-
nificantly with memantine compared with deterioration
with placebo and the nurses’ observation scale for geria-
tric patients’ disturbed behavior also showed differences
in favor of memantine. Memantine therapy resulted in
stabilization of patients with vascular dementia, com-
pared with placebo controls (70, 71).
Primary and Secondary Prevention
The classic modifiable risk factors for vascular de-
mentia include hypertension, cardiac abnormalities such
as atrial fibrillation, smoking, lipid abnormalities, diabe-
tes, and elevated homocysteine levels. Modifying and
treating vascular risk fastors leads to stroke prevention
and lower the risk of Alzheimer’s dementia and VaD.
In the extension of the Systolic Hypertension in Eu-
rope Study (SYST-EUR) long-term antihypertensive
therapy reduced the risk of both Alzheimer’s dementia
and Post stroke vascular dementia by 55% with the treat-
ment with the calcium-channel blocker nitrendipine (18).
Antihypertensive treatment reduced the odds of incident
cognitive impairment by 38% in a 946-participant cohort
of African Americans and it was associated with a 28%
reduction in the risk of recurrent stroke and a 38-55%
reduction in the risk of dementia (72).
In the Perindopril Protection Against Recurrent Stro-
ke Study (PROGRESS) blood pressure lowering in pa-
tients with previous stroke or transient ischemic attack
significant reduction of cognitive decline and dementia
was documented in the active treatment group, com-
pared with the placebo (73, 74).
The Mediterranean diet, with its high content of fish,
seafood, grains, vegetables, citrus fruits and olive oil,
appears to be protective against vascular disease, as well
as moderate physical activity (75, 76). Finally, effortful
mental activities appear to be protective against demen-
tia, both Alzheimer’s and vascular (77 – 85).
Conclusion
Vascular dementia is an important and often over-
looked form of dementia. Projections indicate that it may
become the most common form of dementia in the elder-
ly affected by ischemic heart disease and stroke. Most
cases of vascular dementia present with a subcortical
form of dementia with prominent executive dysfunction
that is usually not recognized as dementia by relatives or
caregivers. Cholinergic treatment may improve the prog-
nosis of the condition. Primary prevention of vascular
dementia appears to depend on early identification and
appropriate control of vascular risk factors. Secondary
prevention, after clinical stroke or silent lacunes, must
include energetic therapy to prevent stroke recurrence.
POST STROKE DEPRESSION
Introduction
Depression is a common mental disorder that presents
with depressed mood, loss of interest or pleasure, feelings
of guilt or low self-worth, disturbed sleep or appetite, low
energy, and poor concentration (86). Post-stroke depres-
sion (PSD) is considered as the most frequent and im-
portant neuropsychiatric consequence of stroke since ap-
proximately one-third of stroke survivors experience
depression. PSD has significant negative consequences on
the recovery of motor and cognitive deficits, functional
recovery and survival after stroke (87). The Diagnostic
and Statistical Manual (DSM) IV categorizes post-stroke
depression as »mood disorder due to a general medical
condition (i.e. stroke)« with the specifiers of depressive
features, major depressive-like episodes, manic features, or
mixed features (88). Major depression and minor depres-
sion are the most frequently recognized expressions of
PSD.
Epidemiology and risk factors
Pooled data on prevalence of all types of PSD in
various populations differs significantly: data from four
community-based studies show mean prevalence of
31,8% (range 30-44%), data from studies carried out in
acute hospitals show prevalence between 25-47%, and
studies done in rehabilitation centers show prevalence
between 35-47% (89 – 93).
The occurrence of PSD peaks three to six months after
stroke and subsequent decline in prevalence at one-year
reaches about to 50% of initial rates. In a study done on
100 stroke patients followed for 18 months, 46% of the
patients had symptoms of PSD in the first two months
after stroke, while only 12% of patients experienced first
symptoms 12 months after stroke. The course of PSD can
be rather lengthy, for example, symptoms of major
depression identified in 27% of stroke patients persisted
for approximately one year, while symptoms of minor
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depression in 20% of stroke patients lasted for more than
two years. Major depression occurs in up to 25% of pa-
tients; and minor depression, which has been defined as a
depressed mood or loss of interest occurs in up to 30% of
patients following stroke (92, 93). Minor depression ap-
peared to be more variable, with both short term and long
term depression occurring in these patients. Prevalence of
major depression from four community-based studies
ranged from 11-15%; from studies carried out in acute
hospitals ranged from 10-27%; in studies done in rehabi-
litation centers ranged from10- 40%. Prevalence of minor
depression from four community-based studies ranged
from 8-12%, from studies carried out in acute hospitals
ranged from 11-20%, in studies done in rehabilitation
centers ranged from 21-44% (91 – 96).
The various risk factors associated with PSD have
included location and size of the stroke, temporal relation
between PSD and stroke, and the size of the ventricles.
Clinical studies have shown that longer duration of PSD
have patients with stroke in the territory of the middle
cerebral artery, compared with patients with posterior
circulation strokes. Robinson et al have shown that there is
so called anterior to posterior gradient which is different
according to the hemisphere involved, being posterior to
anterior for the left hemisphere and anterior to posterior
for the right hemisphere (97). Bogousslavsky et al have
shown that PSD is in strong correlation with lesions in the
subcortical white matter, thalamus, basal ganglia, and
brain steam, rather than cortical lesions with specific
cortical disturbance (23). Starkestein et al. compared the
magnitude of subcortical atrophy in brain CT studies
obtained immediately after stroke. Patients who develop
PSD had a significantly greater degree of atrophy at this
stage than those who did not (98).
There is a higher frequency of left than right strokes in
PSD patients if the symptoms develop in first 10 days, the
relationship disappears if the onset of symptoms was 3
months after stroke. If the symptoms appear ³1 year after
stroke, right sided lesions are more frequent. Overt
sadness is more frequently associated with left (86%) than
right lesions (61%). Crying is also more frequent in left
versus right lesions (50% vr. 20%). With right-side lesions
anosognosia is clearly associated with neglect (95% vr. 34%
for neglect vrs no neglect). Regional cerebral blood flow
values can also be valuable in PSD prediction. Lower
cerebral blood flow (CBF) values in mesial temporal
cortex may reflect dysfunction of limbic system and may
be critical for the occurrence of depressive symptoms in
patients with subcortical strokes. Patients with lower CBF
in the left frontal or right parietooccipital regions were
more depressed in comparison with those with other brain
lesions (23, 97 – 103).
Diagnosis
The most frequently used scale for evaluating depres-
sion in stroke patients is the Hamilton Depression Rating
Scale (HDRS). However, General Health Questionnaire
(GHQ), Hospital Anxiety and Depression Scale (HADS),
Aphasic Depression Rating Scale (ADRS), Beck Depres-
sion Inventory (BDI) or some modified scales such as the
Lausanne Emotion in Acute Stroke Study (LEASS) can
also be used in diagnosis of PSD (98). PSD has a negative
impact on cognitive functioning, and for evaluation of
cognitive functions most frequently used are Mini Mental
State Exam (MMSE) and Montreal Cognitive Assessment
(MoCA) (82, 83, 88).
Clinical manifestation
In acute phase of stroke there are some conditions that
should be distinguished from PSD such as: anosognosia
or poor recognition of the neurological deficit, and fati-
gue classified as pseudodepressive syndrome after stroke.
Also, modified mental processing can affect up to one
third of stroke patients who have no, or only poor,
memory of what actually happened during the acute
phase of stroke. This usually occurs without specific
damage to the anatomical structures involved in memory
processing. Emotional lability, sometimes also referred to
as post stroke emotionalism or catastrophic reactions, is
reported in about 10% of stroke patients. It is an ab-
normal lability of mood during which the patient laughs
or cries for no evident reason, suffers anxiety, apathy and
loss of psychic self-activation (athymhormia). Typically
the patient does not feel the expected emotion associated
with the outward reaction, and patient can with no ap-
parent reason change from laughter to crying (60, 92, 93,
96, 97). The clinical manifestations of PSD are similar to
those of late onset depression, but it is identified in
patients that may have clinically apparent or silent
strokes or subcortical bilateral white matter ischemic
disease. Mostly affectad are patients after the age of 65
years. The symptoms of PSD consist of mood abnor-
malities, neuropsychological disturbances with impair-
ment of executive functions and a greater tendency to
psychomotor retardation, poor insight and impaired
activities of daily living. Vegetative symptoms consist of
disturbances of sleep, libido and low level of energy, were
significantly more frequent among depressed than
non-depressed stroke patients at initial evaluation, and
after 3, 6, 12 and 24 months (91, 92).
There is a bidirectional relationship between stoke
and depression: there is a high prevalence of depression
between stroke patients and there is a higher risk for
stroke in depressed people even when other conventional
stroke risk factors are under control (60). In one study it
have been shown that previous stroke is a risk factor for
PSD (92). In another studies authors shown that patients
with major PSD had significantly more cognitive deficits
than non depressed patients who experienced a similar
location and size of the left hemisphere stroke, this was
not the case for strokes in the right hemisphere (98, 99),
while Lausanne Emotion in stroke study had shown no
statistical significance (100).
When symptoms of depression appear more than one
year after stroke right sided lesions were more frequent.
Stroke severity and disability may cause a reactive de-
pressive process in early stages after stroke, but probably
does not mediate the development of PSD in the long
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term. There was a significantly higher prevalence of PSD
among patients with non-fluent aphasia, but not among
patients with fluent aphasia. The presence of PSD has
been found to have negative impact on recovery of cog-
nitive function, recovery of ability to perform activities of
daily living (ADL), mortality risks (101 – 103).
DESTRO study has shown higher frequency of wo-
men with PSD (35.39% without and 48.56% with PSD)
(90, 104, 105). FINNSTROKE study has shown that
older age as independent predictor of PSD (93), Erriks-
son M et al has shown younger age as predictor of PSD
(106), DESTRO study has shown no statistical signi-
ficance, therefore results are still controversial. Meta-
analyses has shown no statistical significance between
the age and PSD (107). There were 20% of stroke pa-
tients who made no recovery, 60% made complete re-
covery, however, in evaluating recurrent stroke there must
be informations about previous disability. Also, there
were more ADL dependent (11,6% vr 7%), and living
alone (54,8% vr 45,3%) patients without PSD (92, 101,
108).
Treatment and prevention
PSD treatment has the aim to achieve complete symp-
tom remission of the depressive episode that may have a
positive impact on recovery of neurological deficits (109,
110). The efficacy of pharmacotherapy of PSD has been
investigated in several studies with tricyclic antidepres-
sants and selective serotonin reuptake inhibitors. In one
study it was shown that responders to treatment with
antidepressant medication had higher MMSE scores
compared with placebo (109). In another study authors
compared recovery of motor deficit and disability in PSD
patients treated with antidepressant medications versus
placebo finding that treated patients were significantly
more likely to achieve symptom remission (111). Pre-
vention with sertraline in the doses from 50-150 mg/day
has shown during one year in a double blind study that
among treated patients 8,3% developed a PSD, compared
to 22,8% patients on placebo (112). One study shown that
patients treated with nortryptiline had an increased sur-
vival probability at six years (61% vs placebo 34%) (107).
Another study found that nortryptiline (100 mg/day)
compared with fluoxetine (40 mg/day) and placebo had
shown significant improvement (113). Double blind pla-
cebo controled study of fluoxetine (20 mg/day) versus
placebo showed that patients on active treatment expe-
rienced comparable improvement during first 4 weeks, by
12 weeks patients on fluoxetine continued to improve
while those on placebo had experienced recurrence of
symptoms (114). Citalopram and nortryptiline double
blind studies failed to show improvement of cognitive
deficits even in the presence of depression improvement
(115, 116).
Conclusion
It is important to recognize and diagnose post stroke
depression. This is not only because of the increased
suffering depression causes to patients who already have
much to cope with, but because depression after stroke is
associated with worse prognosis and there are evidences
that pharmacological treatment could substantially
improves this outlook.
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